NASDAQ:AVXL Anavex Life Sciences Q4 2026 Earnings Date & Estimates $0.60 -0.07 (-10.86%) Closing price 11/20/2026 03:59 PM EasternExtended Trading$0.61 +0.02 (+3.19%) As of 11/20/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Anavex Life Sciences is estimated to report Q4 2026 earnings on Tuesday, November 24, 2026, before market opens. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ4 2026Announcement DateNovember 24, 2026TimeBefore Market Opens Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Anavex Life Sciences in Q4 2026Anavex Life Sciences is expected to post earnings of -$0.11 per share. In the same quarter a year earlier Anavex Life Sciences reported -$0.11 per share. Anavex Life Sciences last reported on August 25, 2026, posting $0.08 per share and beating the -$0.08 consensus estimate. Anavex Life Sciences has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.11Prior-Year EPS-$0.11Recent Track RecordLast ReportedQ3 2026Last Quarter EPS$0.08 (Beat by +$0.16)EPS Beat Rate7 of last 8 quartersPrepare for the Q4 2026 CallEarnings HistoryCompany ProfileQ3 2026 Earnings ReportQ2 2026 Earnings ReportQ1 2026 Earnings Report Anavex Life Sciences Q4 2026 Earnings FAQ When does Anavex Life Sciences report Q4 2026 earnings? Anavex Life Sciences (NASDAQ:AVXL) is estimated to report Q4 2026 earnings on Tuesday, November 24, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Anavex Life Sciences' Q4 2026 earnings call? Anavex Life Sciences' Q4 2026 earnings conference call is scheduled for Friday, December 11, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Anavex Life Sciences? Analysts expect Anavex Life Sciences to post earnings of -$0.11 per share for Q4 2026. Anavex Life Sciences Earnings HeadlinesAVXL DEADLINE ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important November 30 Deadline in Securities Class Action First Filed by the Firm – AVXLNovember 21 at 10:16 AM | globenewswire.comWhat Does Anavex Life Sciences Corp.'s 6.35% Stock Drop Mean for Investors? The Law Offices of Howard G.November 20 at 2:00 PM | prnewswire.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 21 at 1:00 AM | Porter & Company (Ad)Anavex Life Sciences Corp. (AVXL)November 19 at 11:56 PM | finance.yahoo.comANAVEX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important November 30 Deadline in Securities Class Action First Filed by...November 19 at 3:31 PM | markets.businessinsider.comWhat Should Anavex Life Sciences Corp. Investors Know After 6.35% Stock Drop? The Law Offices of Frank R.November 19 at 1:10 PM | prnewswire.comSee More Anavex Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Anavex Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anavex Life Sciences and other key companies, straight to your email. Email Address About Anavex Life SciencesAnavex Life Sciences (NASDAQ:AVXL) is a clinical-stage biopharmaceutical company that researches and develops treatments for neurological and neurodevelopmental disorders. Its work focuses on investigational medicines intended to affect biological pathways involved in the central nervous system. The company’s lead candidate, blarcamesine (ANAVEX2-73), is an oral investigational drug studied for conditions including Alzheimer’s disease and Rett syndrome. Anavex has also evaluated other drug candidates for neurological disorders. These medicines remain investigational and are not approved treatments. Founded in 2004, Anavex has conducted clinical studies in multiple countries, including the United States, Australia and countries in Europe. Its research has focused in part on sigma-1 receptor biology, which the company investigates as a potential approach to treating diseases of the central nervous system.View Anavex Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/16 - 11/20If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in LimboAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestOwens Corning's Stock Slump May Have a Silver Lining for Dividend InvestorsThe Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity StocksHard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.